Pembrolizumab-induced Mucositis in a Patient with Recurrent Hypopharynx Squamous Cell Cancer

Overview

Journal Laryngoscope

Specialty Otorhinolaryngology

Date 2019 May 11

PMID 31074845

Citations 5

Authors

Meredith S Pelster

Frank Mott

Jan Lewin

Affiliations

Soon will be listed here.

Abstract

Pembrolizumab, an anti-PD-1 checkpoint inhibitor, is used in patients with recurrent or metastatic squamous cell carcinoma of the head and neck who have received prior therapy with a platinum-based regimen. As a monotherapy, it is generally well tolerated, but a small percentage of patients may develop immune-mediated inflammatory reactions. We report a case of mucositis and laryngeal edema in a patient on pembrolizumab and review the literature. Laryngoscope, 130:E140-E143, 2020.

Citing Articles

PD-1/PD-L1 pathway: Current research in breast cancer.

Syamsu S, Faruk M, Smaradania N, Sampepajung E, Pranoto A, Irsandy F Breast Dis. 2024; 43(1):79-92.

PMID: 38701137 PMC: 11091639. DOI: 10.3233/BD-249006.

A meta-analysis: the clinical value of PD-1 inhibitor or protein tyrosine kinase inhibitors in the treatment of advanced osteosarcoma.

Shi B, Chang J, Sun X, Ma X, Zhao P, Zhou C Front Oncol. 2023; 13:1148735.

PMID: 37377920 PMC: 10291171. DOI: 10.3389/fonc.2023.1148735.

Emerging Role of PD-1/PD-L1 Inhibitors in Chronic Liver Diseases.

Singh V, Khurana A, Allawadhi P, Banothu A, Bharani K, Weiskirchen R Front Pharmacol. 2022; 12:790963.

PMID: 35002724 PMC: 8733625. DOI: 10.3389/fphar.2021.790963.

Management of pembrolizumab-induced steroid refractory mucositis with infliximab: A case report.

Dang H, Sun J, Wang G, Renner G, Layfield L, Hilli J World J Clin Cases. 2020; 8(18):4100-4108.

PMID: 33024767 PMC: 7520797. DOI: 10.12998/wjcc.v8.i18.4100.

PD-1/PD-L1 pathway: current researches in cancer.

Han Y, Liu D, Li L Am J Cancer Res. 2020; 10(3):727-742.

PMID: 32266087 PMC: 7136921.